Related Experiment Video

Updated: May 21, 2026

SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
08:29

SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer

Published on: November 1, 2019

SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane

Jian Huang1, Jie Yan, Jian Zhang

  • 1Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai 200025, China.

Nature Communications
|June 21, 2012
PubMed

Insights

SUMO1 modification of the tumor suppressor PTEN (phosphatase and tensin homologue) is crucial for its membrane association. This enhances PTEN

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • The tumor suppressor PTEN (phosphatase and tensin homologue) opposes the PI3K/AKT pathway by dephosphorylating PIP3.
  • The mechanism of PTEN's interaction with PIP3 at the plasma membrane is not fully understood.

Purpose of the Study:

  • To elucidate the role of SUMO1 modification in PTEN's membrane association and tumor suppressor function.
  • To investigate how PTEN interacts with its substrate PIP3 at the plasma membrane.

Main Methods:

  • SUMO1 modification analysis of PTEN at specific lysine sites (K266 and K254) within the C2 domain.
  • Assessment of PTEN's membrane association and its impact on the PI3K/AKT pathway.
  • In vivo studies to evaluate the effect on anchorage-independent cell proliferation and tumor growth.

Main Results:

  • PTEN undergoes covalent SUMO1 modification at K266 and K254 in its C2 domain.
  • SUMO1 modification at K266 facilitates PTEN's cooperative binding to the plasma membrane via electrostatic interactions.
  • This SUMO1-mediated membrane association leads to downregulation of the PI3K/AKT pathway, suppressing cell proliferation and tumor growth.

Conclusions:

  • SUMO1 modification is essential for PTEN's tumor suppressor activity.
  • SUMO1 conjugation controls PTEN membrane localization, thereby regulating the PI3K/AKT pathway.
  • This study reveals a key molecular mechanism linking SUMOylation to PTEN function in cancer suppression.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...